Skip to content

Prospective Data Collection to Compare RAL for Hysterectomies and Other Indications in to Conventional Laparoscopy

Prospective Data Collection to Compare Robotically Assisted Laparoscopy for Hysterectomies and Other Selected Indications in Comparison to Conventional Laparoscopy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05613816
Enrollment
78
Registered
2022-11-14
Start date
2022-09-22
Completion date
2024-01-31
Last updated
2026-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine Diseases

Brief summary

This is a prospective, single-center, observational clinical trial at the Department of Women's Health of the University Hospital Tübingen.

Detailed description

This is a prospective, single-center, observational clinical trial at the Department of Women's Health of the University Hospital Tübingen. 100 patients affected by uterine diseases with indication for hysterectomy undergo treatment with robotically assisted laparoscopic procedures using the Senhance Surgical System (See Synopsis - Indication A) and are compared to a cohort of 200 patients treated with conventional laparoscopic surgery from a similar ongoing study (Ethics vote: 621 /2018BO1). 100 patients affected by other uterine conditions / adnexal conditions that require uterine/adnexal/tubal surgery (see Synopsis - Indication B) undergo treatment with robotically assisted laparoscopic procedures using the Senhance Surgical System and are compared to a cohort of 200 patients with indication for other uterine conditions / adnexal conditions that require uterine/adnexal/tubal surgery (see Synopsis - Indication B) who underwent conventional laparoscopic surgery at the Department of Women's Health in the past. At the end of patient recruitment, surgical procedure times, estimated blood loss, intra- and post-operative complications and the percentage of conversions from the robotic assisted treatment/conventional laparoscopic surgery to multiple access and/or to a laparotomic (open) approach will be documented. Patients will answer questionnaires (German version of the Short Form-36health survey questionnaire (Medical Outcomes Trust), German version of the female sexual function index (FSFI)) at baseline and at 3 and 6 months of follow-up. A questionnaire for patient satisfaction will be answered one day post procedural, at discharge and at 3 and 6 months follow-up.

Interventions

PROCEDURESenhance Surgical System

100 patients affected by uterine diseases with indication for hysterectomy undergo treatment with robotically assisted laparoscopic procedures using the Senhance Surgical System

Sponsors

University Hospital Tuebingen
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age ≥18 years * BMI ≤40 kg/m2 * indication for hysterectomy for benign disease or prophylactic surgery due to hereditary cancer * indication for radical hysterectomy and/or pelvic-/para-aortic (sentinel-node) lymphadenectomy for cervical cancer * indication for modified radical hysterectomy and/or pelvic-/para-aortic (sentinel-node) lymphadenectomy for endometrial cancer * indication for other uterine conditions / adnexal conditions that require uterine/adnexal/tubal surgery: Fibroids, Endometriomas, Cystic masses, Ectopic pregnancies, Sactosalpinx, Inflammatory adnexal disease, Opportunistic salpingectomy as part of hysterectomy or exclusively, Cervico-/Sacrokolpopexy * size of uterus and vagina allows for retrieval by the vaginal route in cancer patients * written informed consent

Exclusion criteria

* known extensive intra-abdominal adhesions * anaesthesiological contraindications to laparoscopy * women with pacemaker or other implants where electrosurgery is to be avoided * women with known defects of the hemostasis * pregnancy * other internal or anatomical criteria that preclude a minimal invasive approach * inability to understand patient information

Design outcomes

Primary

MeasureTime frameDescription
operating time60 minutestime from first incision to skin closure

Secondary

MeasureTime frameDescription
time under narcosis60 minutesduration of time in which the study participant is under the influence of a narcotic substance
console time60 minutesduration of time during which a surgeon is controlling the surgical robot from a console
estimated blood loss (milliliters)60 minutesusing the following formula: ((Hemoglobin concentration preoperative (g/l)) - (Hemoglobin 1st day postoperative (g/l)))/((Hemoglobin preoperative (g/l)) - (Hemoglobin 1st day postoperative (g/l)))/2) × 1000
conversion to other surgical procedures (e. g. open)60 minutesif the original surgical plan during surgery is altered and switched to a different type of surgery to address unforeseen complications or difficulties that arise during the operation
time to discharge60 minuteslength of time that a patient spends in the hospital before they are well enough to be released and sent home
intraoperative complications60 minutes(occurring during the surgical procedure)
perioperative complications24 hours(occurring less than 24h after the surgical procedure)
postoperative complications6 months(occurring more than 24h after the surgical procedure up to 6 months after surgical procedure)
German version of the Short Form-36health survey questionnaire (Medical Outcomes Trust)at baseline, and at 3 and 6 months of follow-upThe SF-36 questionnaire (Short Form 36 Health Survey) is a widely used measure of health status and quality of life. The questionnaire consists of 36 items that measure eight health domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The scores range from 0 to 100 for each domain, with higher scores indicating better health status. Therefore, higher scores on the SF-36 indicate a better outcome.
German version of the female sexual function index (FSFI) questionnaireat baseline, and at 3 and 6 months of follow-upfemale sexual function index: a multidimensional self-report instrument for the assessment of female sexual function; The total composite sexual function score is a sum of domain scores and ranges from 2.0 (not sexually active and no desire) to 36.0. Higher scores on the FSFI indicate better sexual function.
Questionnaire for patient satisfactionat one day post procedural, at discharge and at 3 and 6 months follow-upIncluding A Pain Score ( No Pain 0 - Worst Possible Pain 10) and B Satisfaction with: the severity of the pain; the quality of recovery; the scars; the surgery overall (Scale satisfaction: Extremely dissatisfied -- Dissatisfied -- Somewhat dissatisfied -- Neither satisfied nor dissatisfied -- Somewhat satisfied -- Satisfied -- Extremely satisfied)

Countries

Germany

Contacts

PRINCIPAL_INVESTIGATORJürgen Andress, Dr

Department für Frauengesundheit am Universitätsklinikum Tübingen

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026